论文部分内容阅读
目的观察孟鲁司特联合布地奈德吸入治疗儿童支气管哮喘的临床疗效。方法选取中、重度支气管哮喘急性发作患儿30例,随机分对照组和治疗组,每组各15例。对照组采用激素、多索茶碱常规治疗,治疗组采用布地奈德每日两次雾化吸入、孟鲁司特4mg,1次/d睡前口服治疗。疗程均为10d。记录患者临床症状缓解时间;两组治疗前和治疗后10d各进行一次肺功能测定和嗜酸性粒细胞计数,数据进行统计学分析。结果两组患儿经过治疗后肺功能FEV1/FVC%、PEF均明显上升(P<0.05),治疗组较对照组上升更明显(P<0.05)。并且治疗组患儿临床症咳嗽、喘息的缓解时间明显短于对照组(P<0.05)。经过治疗后两组患儿EOS计数均下降明显(P<0.05),治疗组与对照组相比下降更为明显(P<0.05)。结论孟鲁司特联合布地奈德吸入治疗可以有效地改善中、重度哮喘患者的肺功能,缓解哮喘症状,降低EOS计数,从而有效的控制哮喘的发作。
Objective To observe the clinical efficacy of inhalation of montelukast combined with budesonide in children with bronchial asthma. Methods Thirty children with acute exacerbation of moderate and severe bronchial asthma were randomly divided into control group and treatment group, 15 cases in each group. The control group was treated with hormone and doxofylline. The treatment group was treated with inhaled budesonide twice a day, montelukast 4 mg, once a day before bedtime oral treatment. Treatment are 10d. The patient’s clinical symptom relief time was recorded. The pulmonary function test and eosinophil count were performed before treatment and 10 days after treatment respectively. The data were statistically analyzed. Results After treatment, the FEV1 / FVC% and PEF of pulmonary function in both groups were significantly increased (P <0.05), and the treatment group increased more significantly than the control group (P <0.05). And clinical treatment of children with cough, asthma relief time was significantly shorter than the control group (P <0.05). After treatment, the EOS count of both groups dropped significantly (P <0.05), and the treatment group decreased more obviously than the control group (P <0.05). Conclusion Montelukast combined with budesonide inhalation can effectively improve the lung function, alleviate the asthma symptoms and reduce the EOS count in patients with moderate and severe asthma, so as to effectively control the onset of asthma.